Alzheimer's disease (AD) is the most common neurodegenerative disease, with cognitive
decline as the primary clinical feature. According to epidemiological statistics, 50 million …

The history of Alzheimer's disease (AD) started in 1907, but we needed to wait until the end
of the century to identify the components of pathological hallmarks and genetic subtypes and …

Circulating microRNAs (cimiRNAs) are a class of non-encoding RNAs found in bodily fluids
such as blood, cerebrospinal fluid (CSF) and tears. CimiRNAs have been implicated as …

There are currently no validated biomarkers which can be used to accurately diagnose
Alzheimer's disease (AD) or to distinguish it from other dementia-causing neuropathologies …

There is no consensus for a blood-based test for the early diagnosis of Alzheimer's disease
(AD). Expression profiling of small non-coding RNA's, microRNA (miRNA), has revealed …

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by
decreased memory and cognitive functions. Exosomes carry a variety of important …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the main cause
of dementia among the elderly worldwide. Despite intense efforts to develop drugs for …

Neurodegenerative diseases originate from neuronal loss in the central nervous system
(CNS). These debilitating diseases progress with age and have become common due to an …

The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …

Alzheimer's disease is a progressive, clinically heterogeneous, and particularly complex
neurodegenerative disease characterized by a decline in cognition. Over the last two …